Background:  The α/β hydrolase superfamily comprise diverse members that are involved in important biochemical processes and related to various diseases. They have unrelated sequences, various substrates and different kinds of catalytic activities, yet they share the same canonical α/β hydrolase fold, which consists of an eightstranded parallel α/β structure. They are also characterized by a catalytic triad composed of a histidine, an acid and a nucleophile. Members of this superfamily are often drug targets for treating diseases, such as diabetes, Alzheimer’s disease, obesity and blood clotting disorders. The α/β hydrolase domain containing (ABHD) gene subfamily is comprised of 15 mostly uncharacterized members, most of which utilize a serine nucleophile to form the G-X-S-X-G nucleophile elbow. ABHD1 plays a role in metabolizing smoking xenobiotics. ABHD2 participates in the development of atherosclerosis. ABHD4 is involved in an alternative synthesis pathway of NAE. Mutations in ABHD5 contribute to Chanarin-Dorfman syndrome. ABDH6 may play a role in nervous system metabolism and signaling. ABHD13 is a 337 amino acid single-pass membrane protein that belongs to the ABHD family.

Description: Rabbit polyclonal to ABHD13

Immunogen: KLH conjugated synthetic peptide derived from ABHD13

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 39 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-200;

·Immunocytochemistry: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.